Regulatory Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Pharmaceutical TechnologyBoehringer Ingelheim has received Japan's MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.RespiratoryRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Another LAG-3 setback as Regeneron drug fails phase 3 trialNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Regulatory Bayer gets swift review for Kerendia in type 1 diabetes pharminent May 21, 2026 Regulatory Pazdur declines to announce candidacy for vacated FDA commissioner role pharminent May 20, 2026 Regulatory VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain pharminent May 19, 2026
